Wells Fargo’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-154
Closed -$150 7753
2023
Q3
$150 Buy
154
+11
+8% +$8 ﹤0.01% 6653
2023
Q2
$100 Buy
143
+23
+19% +$14 ﹤0.01% 6868
2023
Q1
$79 Buy
120
+2
+2% +$3 ﹤0.01% 6989
2022
Q4
$177 Buy
118
+1
+0.9% +$2 ﹤0.01% 6652
2022
Q3
$0 Hold
117
﹤0.01% 7668
2022
Q2
$1K Buy
117
+47
+67% +$425 ﹤0.01% 6670
2022
Q1
$1K Hold
70
﹤0.01% 6898
2021
Q4
$1K Buy
70
+3
+4% +$54 ﹤0.01% 7113
2021
Q3
$2K Hold
67
﹤0.01% 6617
2021
Q2
$2K Buy
67
+4
+6% +$164 ﹤0.01% 6580
2021
Q1
$3K Buy
63
+55
+688% +$3.02K ﹤0.01% 6604
2020
Q4
$0 Buy
8
+7
+700% +$220 ﹤0.01% 7211
2020
Q3
$0 Hold
1
﹤0.01% 7101
2020
Q2
$0 Hold
1
﹤0.01% 7004
2020
Q1
$0 Buy
+1
New +$78 ﹤0.01% 7007
2017
Q4
Hold
0
6588
2017
Q3
Hold
0
6525
2017
Q2
Hold
0
6515
2017
Q1
Hold
0
6571
2016
Q4
Hold
0
6501
2016
Q3
Hold
0
6397
2016
Q2
Hold
0
6397
2016
Q1
Hold
0
6504
2015
Q4
Sell
-1
Closed -$1.3K 6125
2015
Q3
$1K Sell
1
-6
-86% -$11.6K ﹤0.01% 6092
2015
Q2
$15K Buy
7
+1
+17% +$3.14K ﹤0.01% 5695
2015
Q1
$19K Hold
6
﹤0.01% 5406
2014
Q4
$21K Sell
6
-1
-14% -$3.54K ﹤0.01% 5350
2014
Q3
$25K Buy
7
+1
+17% +$3.89K ﹤0.01% 5211
2014
Q2
$25K Sell
6
-1
-14% -$3.76K ﹤0.01% 5283
2014
Q1
$30K Hold
7
﹤0.01% 5097
2013
Q4
$27K Sell
7
-24
-77% -$90.9K ﹤0.01% 4931
2013
Q3
$120K Hold
31
﹤0.01% 4412
2013
Q2
$303K Buy
+31
New +$343K ﹤0.01% 3922

Other funds holding FRTX

Wells Fargo's FRTX Position: Q4 2023 in Review

Wells Fargo sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2023, closing a stake of 154 shares — an estimated $150 sold.

Wells Fargo first reported a position in FRTX in Q2 2013 and held it in 25 quarters. The position peaked at $303K in Q2 2013. 1 fund tracked by Wall St. Rank holds FRTX as of Q4 2023.

  • Wells Fargo reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Wells Fargo sold 154 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $150.
  • Wells Fargo first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
  • Wells Fargo's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $303K in Q2 2013.
  • 1 fund tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.